NCT03022435View on ClinicalTrials.gov

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

TIV

Influenza Virus Vaccine Suspension for Intramuscular Injection

BIOLOGICAL

High-Dose TIV

High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe

BIOLOGICAL

LAIV

Live, attenuated influenza vaccine for Intranasal Spray

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Stanford University

OTHER

NCT03022435 - T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012 | Biotech Hunter | Biotech Hunter